EGFR and non-small cell lung carcinoma: We previously demonstrated that different c-Src inhibitors act through several mechanisms in sensitive or erlotinib-resistant NSCLC models and that the combination of c-Src or MEK inhibitors with EGFR-TKI (in EGFR or RAS mutated models, respectively) leads to higher benefits compared to single treatment in NSCLCs.